A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutaded Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
May 1, 2014
End Date
November 3, 2015
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
May 1, 2014
End Date
November 3, 2015